Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 284 results
A test tube in a laboratory setting

Jun 1, 2026

Q1 2026: When Pharma AI Partnerships Crossed a Threshold

The first quarter of 2026 marked a pivotal moment for artificial intelligence in the pharmaceutical sector, characterized not just by an increase in partnerships, but by a fundamental shift in how these collaborations are structured and integrated into the industry.In Q1 2026, the number of significant AI partnerships doubled to thirty-six compared to the same period in 2025. However, the real significance lies in the nature of these deals. They reflect a transition from experimental pilot proje
A close-up of a cell culture dish in a lab setting, with a pipette above it.

May 28, 2026

Pamela Carroll ’85 uses AI in biotechnology to tackle formerly “undruggable” drivers of disease

Pamela Carroll, a 1985 graduate of Saint Michael’s College, is pioneering the integration of artificial intelligence (AI) in biotechnology, focusing on previously "undruggable" disease drivers. Her career trajectory, which includes significant roles in both research and business, highlights the transformative potential of AI in drug discovery and development.Carroll's journey began at the National Cancer Institute, where her fascination with cell biology took root. This interest propelled her th
A test tube with protein solution in a dimly lit lab

May 28, 2026

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Sino Biological's innovative cell-free protein synthesis technology has been pivotal in a recent study conducted by Tencent AI for Life Sciences Lab, as published in *Nature Communications*. This collaboration highlights the integration of AI in protein design, enabling the rapid validation of proteins that exhibit enhanced activity, stability, and multifunctionality.The study addresses a significant challenge in protein engineering: the transition from AI-generated amino acid sequences to funct
Molecular model on a lab table with a research notebook

May 28, 2026

Hoffman Predicts AI-Driven Drug Discovery Bonanza

Reid Hoffman, co-founder of LinkedIn and Manas AI, recently highlighted the transformative potential of AI in drug discovery during an appearance on "The Possible Podcast." He emphasized that the market for AI-driven drug discovery could surpass that of current AI chatbot applications.Hoffman pointed out that the existing chatbot market, dominated by companies like OpenAI and Anthropic, is significant, but the opportunities in drug discovery are even greater. He noted that AI technologies can si
A minimalist representation of a drug capsule and heart symbol in a dark palette.

May 28, 2026

AI-Designed Drug Enters Phase I Trial

Quotient Sciences has launched a Phase I clinical trial for a novel drug product, developed using artificial intelligence (AI), marking a potential breakthrough in AI-driven drug formulation.The trial, conducted at Quotient Sciences' UK facility, has received approval from the MHRA and aims to assess the safety and pharmacokinetics of the drug in healthy volunteers. This initiative is significant as it seeks to validate AI's role in drug development, potentially enhancing formulation design and
A minimalist illustration of a pill bottle representing non-opioid pain therapy.

May 28, 2026

Redwood AI Bridges Markets and Medicine with DTC Eligibility and Pharma Partnership

Redwood AI is making significant strides in the life sciences sector by securing DTC eligibility for US trading and partnering with Resilience Biosciences to develop non-opioid pain therapies.This week, Redwood AI has advanced its dual growth strategy, marking its entry into life sciences through a collaboration with Resilience Biosciences. The partnership aims to tackle the pressing issue of finding alternatives to opioid pain management. Utilizing its advanced computational chemistry platform,
A non-opioid therapeutic compound in a laboratory setting

May 28, 2026

Redwood AI Moves on Two Fronts: US Trading Clearance and Pharma Partnership to Drive Commercial Mome

Redwood AI is making significant strides in both market accessibility and pharmaceutical collaboration, aiming to enhance its commercial potential.The company has recently achieved DTC eligibility for its shares, facilitating easier trading for US investors. This move is designed to improve liquidity and trading efficiency, addressing previous challenges associated with manual processes in the OTCQB market. Alongside this, Redwood AI has formed a partnership with Resilience Biosciences to develo
A pill bottle on a desk with patent documents in a natural light setting.

May 28, 2026

Redwood AI and Resilience Biosciences Forge a Patent-Savvy Path to Non-Opioid Therapies

Redwood AI and Resilience Biosciences are pioneering a novel approach in drug discovery by integrating patent analysis into the early stages of developing non-opioid therapies.This collaboration focuses on addressing the urgent need for non-addictive treatments for opioid withdrawal and associated neurocognitive symptoms. By utilizing Redwood's Reactosphere platform, Resilience Biosciences aims to streamline the drug development process, ensuring that potential candidates are not only biological
A laboratory vial filled with a colorful liquid in a dimly lit lab setting.

May 27, 2026

Verge, following trial failure, rebrands its AI drug discovery ambitions

Verge Genomics is undergoing a significant transformation, rebranding itself as Verge Labs to focus on providing data-driven insights for drug developers. This shift comes after a disappointing trial outcome for its AI-driven ALS treatment, VRG50635, which failed to demonstrate efficacy in patients.The rebranding follows a drastic reduction in workforce, with about 90% of employees laid off. CEO Alice Zhang emphasized that setbacks are common in drug development, whether through AI or traditiona
A petri dish with a drug compound in a lab setting

May 27, 2026

Isomorphic Labs has turned AI drug discovery into a 2.1B capital story

Isomorphic Labs has successfully raised $2.1 billion in a Series B funding round, reflecting strong investor confidence in its AI-driven drug discovery platform.The Alphabet-supported company, helmed by Demis Hassabis, announced that the funding will enhance its AI drug design engine, IsoDDE, and expand its global reach while advancing its pipeline towards clinical trials. This significant financial backing, led by Thrive Capital along with other notable investors, underscores a growing belief t
A minimalist illustration of a pill and a molecule on a solid background.

May 27, 2026

Ex-Palantir team bags $12M seed to build the AI operating system pharma has been missing

Perceptic, a London-based startup, has raised $12 million in seed funding to develop an integrated AI platform aimed at revolutionizing the drug development process, which is currently hindered by fragmented systems. This initiative seeks to streamline the journey of a drug from initial discovery through clinical trials, addressing inefficiencies that plague many pharmaceutical companies.The founders of Perceptic, who previously played pivotal roles in developing Palantir’s AI products for life
Minimalist illustration of an RNA strand and data points

May 26, 2026

Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery

A recent episode of the Beyond Biotech podcast features insights from Dr. Stéphane Barges, CEO of Lexogen, discussing the pivotal role of RNA sequencing in AI-driven drug discovery.In the podcast, Dr. Barges emphasizes that high-quality data tailored for AI applications is crucial for enhancing target identification and decreasing drug development failures. He advocates for datasets that are meticulously designed to address specific scientific questions, underscoring the importance of precision